Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Imugene Limited ( (AU:IMU) ) has provided an update.
Imugene Limited announced its progress in developing cancer therapies, with a 57% complete response rate in blood cancer treatments and plans to initiate a pivotal Phase 2/3 trial in 2026. The company is also advancing its novel virus therapies for solid cancers, showing promising results in bile tract cancer, and is actively pursuing partnerships and cost control measures to enhance its market position.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited is a clinical-stage cancer company specializing in the development of drug products in CAR T cell therapy and oncolytic viruses. The company focuses on creating off-the-shelf allogeneic CAR T therapies targeting blood cancers and novel viruses aimed at treating solid cancers.
Average Trading Volume: 18,435,306
Technical Sentiment Signal: Sell
Current Market Cap: A$97.07M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.